SCHEMBL25156876

SCHEMBL25156876

CCNc1ncc2c(-c3ccc4ncncc4c3)c[nH]c2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 2/20 0.55
▸ DYRK1A Q13627 7/20 0.42
▸ CLK3 P49761 3/20 0.42
▸ CLK2 P49760 2/20 0.42
▸ BRD4 O60885 2/20 0.42
▸ LATS1 O95835 1/20 0.39
▸ PIK3CD O00329 1/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ EGFR P00533 4/20 0.39
▸ CLK1 P49759 2/20 0.38
▸ CLK4 Q9HAZ1 2/20 0.38
▸ CD38 P28907 1/20 0.38
▸ GSK3B P49841 2/20 0.38
▸ FGFR4 P22455 1/20 0.37
▸ DYRK3 O43781 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ DYRK2 Q92630 1/20 0.35
▸ DYRK4 Q9NR20 1/20 0.35
▸ DYRK1B Q9Y463 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30347844 1.00 TDO2 (0.55) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25157142 0.88 TDO2 (0.52) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25519960 0.88 TDO2 (0.52) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25157140 0.87 TDO2 (0.58) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL30347328 0.87 TDO2 (0.58) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25157609 0.86 TDO2 (0.50) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL30348246 0.86 TDO2 (0.50) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL30407329 0.86 TDO2 (0.50) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25519967 0.86 TDO2 (0.50) TDO2DYRK1ACLK3CLK2BRD4
SCHEMBL25519972 0.86 TDO2 (0.52) TDO2DYRK1ACLK3CLK2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-04-24 — — US claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 TDO2 539/4885DYRK1A 1/4885CLK3 1147/4885
US-20250129104-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 TDO2 539/4885DYRK1A 1/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback